Marshall Wace, LLP Spero Therapeutics, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.35 - $2.0 $18,185 - $26,942	13,471 Added 26.46%	64,388 $93,000
Q4 2022 Feb 14, 2023	SELL	$1.55 - $2.12 $210,262 - $287,584	-135,653 Reduced 72.71%	50,917 $88,000
Q3 2022 Nov 14, 2022	BUY	$0.68 - $2.2 $102,136 - $330,442	150,201 Added 412.99%	186,570 $374,000
Q2 2022 Aug 15, 2022	BUY	$0.74 - $7.44 $7,653 - $76,944	10,342 Added 39.74%	36,369 $27,000
Q1 2022 May 16, 2022	BUY	$7.87 - $15.15 $204,832 - $394,309	26,027 New	26,027 $227,000
Q3 2019 Nov 14, 2019	SELL	$9.01 - $12.55 $159,467 - $222,122	-17,699 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$10.25 - $14.36 $149,906 - $210,015	14,625 Added 475.76%	17,699 $204,000
Q1 2019 May 14, 2019	BUY	$6.26 - $13.31 $19,243 - $40,914	3,074 New	3,074 $39,000

13.8M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $28.8M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.